Protocol Ledger

NCT06267001 · Phase III · TERMINATED

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Interventional Phase III clinical trial protocol NCT06267001 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-21 Enrollment: 56 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06267001
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)56 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06267001
Protocol FieldVerified Registry Value
NCT IdentifierNCT06267001
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment56 participants (ACTUAL)
Registered Start Date2024-03-21
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06267001
Hospital Research SiteLocationSite Profile
Sunshine Coast University HospitalBirtinya, AustraliaOpen Hospital Dossier ->
Monash HealthClayton, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI